U
Umed
Biotech & Life Sciences · London, United Kingdom · Founded 2018
A technology platform embedded across a global network of healthcare providers that automates the process of building prospective, protocolized patient registries MoreLess
uMed is a healthcare technology company that accelerates medical research by building consented patient cohorts and generating real-time clinical data insights. The company serves life science companies, healthcare professionals, and patients. Operating in the medical research and healthcare sectors, uMed's business model focuses on creating unique, exclusive data that meets specific research requirements. This data is generated by integrating clinical outcomes from deeply characterized patient cohorts. uMed makes money by providing these valuable data insights and research capabilities to its clients. The company also empowers patients to participate in relevant medical research opportunities from the comfort of their homes, while healthcare professionals benefit from automated processes that reduce their workload and enable participation in more studies.
Keywords: medical research, patient cohorts, clinical data, healthcare technology, life sciences, data insights, patient engagement, research automation, healthcare professionals, real-time data.
Talent graph
Umed's talent
Source: Dealroom Talent Intelligence.
Investors
4 investors on Umed's cap table
Sourced from Dealroom's funding and investor records.




Global footprint
Where Umed has talent and traffic
team presence
Market sentiment
What the market is saying about Umed
An AI-synthesized read of the highest-engagement posts about Umed on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Umed on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.